Breakeven achieved in the base business, with strong eRX growth following CardLink's launch and TeleClinic doubling sales. 2024 revenue is guided to grow 5–10%, with increased investment in eRX customer acquisition impacting EBITDA, but long-term profitability targets remain intact.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.